Correlation of serum alanine aminotransferase and aspartate aminotransferase with coronary heart disease

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 4399-4404

  Shen, Jianying ^a   Zhang, Jingying ^a   Wen, Jing ^a   Ming, Qiang ^a   Zhang, Ji ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Coronary heart disease; Risk

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; TRIACYLGLYCEROL; URIC ACID;

ANGIOCARDIOGRAPHY; ARTICLE; BIOCHEMICAL ANALYSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DYSLIPIDEMIA; EDUCATION; FAMILY HISTORY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCUPATION; SMOKING;

EID: 84929379020     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Agrawal S and Mastana S. Genetics of coronary heart disease with reference to ApoAI-CIII-AIV gene region. World J Cardiol 2014; 6: 755-763.
2. Tan ST, Scott W, Panoulas V, Sehmi J, Zhang W, Scott J, Elliott P, Chambers J and Kooner JS. Coronary heart disease in Indian Asians. Glob Cardiol Sci Pract 2014; 2014: 13-23.
3. Akhabue E, Thiboutot J, Cheng JW, Vittorio TJ, Christodoulidis G, Grady KM, Lerakis S and Kosmas CE. New and emerging risk factors for coronary heart disease. Am J Med Sci 2014; 347: 151-158.
4. Anthony D, George P and Eaton CB. Cardiac risk factors: noninvasive testing to detect coronary heart disease. FP Essent 2014; 421: 21-27.
5. Barbagallo CM, Averna MR, Amato S, Marino G, Labisi M, Rao AC, Barbagallo M, Cupidi GF and Notarbartolo A. Apolipoprotein profile in type II diabetic patients with and without coronary heart disease. Acta Diabetol Lat 1990; 27: 371-377.
6. Lindner J, Schmechel H, Hanefeld M, Sch-wanebeck U and Bauch K. [Coronary heart disease and insulin concentration in type II diabetic patients-results of a diabetes intervention study]. Z Gesamte Inn Med 1992; 47: 246-250.
7. Paynter NP, Crainiceanu CM, Sharrett AR, Chambless LE and Coresh J. Effect of correcting for long-term variation in major coronary heart disease risk factors: relative hazard estimation and risk prediction in the Athero-sclerosis Risk in Communities Study. Ann Epidemiol 2012; 22: 191-197.
8. Cao W, Zhao C, Shen C and Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One 2013; 8: e82092.
9. Carobene A, Braga F, Roraas T, Sandberg S and Bartlett WA. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase. Clin Chem Lab Med 2013; 51: 1997-2007.
10. Gurung RB, Purbe B, Gyawali P and Risal P. The ratio of aspartate aminotransferase to alanine aminotransferase (AST/ALT): the correlation of value with underlying severity of alcoholic liver disease. Kathmandu Univ Med J (KUMJ) 2013; 11: 233-236.
11. Torres DM and Harrison SA. NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis. Nat Rev Gastroenterol Hepatol 2013; 10: 510-511.
12. Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K, Hiasa Y, Matsuura B and Onji M. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol 2012; 47: 696-703.
13. Miura Y. [Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)]. Nihon Rinsho 1999; 57 Suppl: 320-325.
14. Okabe H. [Aspartate aminotransferase]. Nihon Rinsho 1995; 53: 1141-1145.
15. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T and Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22: 437-443.
16. Gefeller O and Steinberg H. Cuff size and hypertension diagnosis. Epidemiology 1992; 3: 73-75.
17. Somani BL, Bangar SS and Bhalwar R. American Diabetes Association criteria for diabetes diagnosis. Another perspective. Diabetes Care 1999; 22: 366.
18. Jander S and Stegemann E. [Carotid atherosclerosis in coronary heart disease]. Dtsch Med Wochenschr 2014; 139: 1224-1227.
19. Makarova NA. [The role of compensatory mechanisms in pathogenesis of coronary heart disease]. Klin Med (Mosk) 2013; 91: 4-9.
20. Dalen JE, Alpert JS, Goldberg RJ and Weinstein RS. The epidemic of the 20(th) century: coronary heart disease. Am J Med 2014; 127: 807-812.
21. Anthony D, George P and Eaton CB. Cardiac risk factors: environmental, sociodemographic, and behavioral cardiovascular risk factors. FP Essent 2014; 421: 16-20.
22. Anthony D, George P and Eaton CB. Cardiac risk factors: biomarkers and genetic tests to determine cardiovascular risk. FP Essent 2014; 421: 11-15.
23. de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R and de la Fuente B. Role of insulin resistance and adipocytokines on serum alanine aminotransferase in obese patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 2013; 17: 2059-2064.
24. Verma S, Jensen D, Hart J and Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013; 33: 1398-1405.
25. Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I and Pedersen TR. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-3852.
26. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E and Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544-1560.
27. Lu H, Zeng L, Liang B, Shu X and Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009; 40: 571-575.
28. Lonardo A, Sookoian S, Chonchol M, Loria P and Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19: 5177-5192.
29. Targher G and Day CP. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. Hepatology 2011; 53: 375.
30. Yoneda K, Katayama Y, Koike T and Tanimizu I. A homogeneous assay system of aspartate aminotransferase iso-enzymes using proteases and application for clinical evaluation of myocardial infarction. J Clin Lab Anal 1992; 6: 362-367.
31. Yoneda K, Katayama Y, Takagi Y, Gomi K and Matsuyama T. [Early diagnosis and detection of successful reperfusion by mitochondrial-AST/soluble-AST ratio after acute myocardial infarction]. Rinsho Byori 1995; 43: 74-80.
32. Jin JJ, Xu YL and Zheng Y. [Effects of acupoint-injection of Kaixilai on TG, TC, MDA, SOD, AST and ALT in the patient of non-alcoholic fatty liver]. Zhongguo Zhen Jiu 2006; 26: 100-102.